I feel like the last sentence of the article is very positive too. I've highlighted a couple of bits that jumped out at me. I understand it may be in relation to previously reported results from the phase II trial, but it just seems the language used is very direct and positive.
"Sheba’s researchers are optimistic that patients will continue to respond favorably to Zantrene as the trial progresses, reporting results as they are analyzed over the study period so that the treatment can be approved for integration into regular clinical use as soon as possible."
RAC media coverage, page-1279
-
- There are more pages in this discussion • 1,007 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.88 |
Change
0.025(1.35%) |
Mkt cap ! $319.4M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.89 | $1.85 | $74.38K | 39.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18943 | $1.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.88 | 199 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |